OzempicvsSaxenda

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a natural gut hormone released after eating. It prompts the pancreas to release more insulin when blood sugar is high, suppresses glucagon (a hormone that raises blood sugar), and slows stomach emptying. It also acts on appetite centers in the brain to reduce hunger and food intake, which is why many people eat less and lose some weight.

Saxenda's active ingredient is liraglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural gut hormone released after eating. By activating GLP-1 receptors in the brain's appetite centers, it increases feelings of fullness and reduces hunger, which tends to lower how many calories you eat. It also slows stomach emptying, so food stays in the stomach longer. Because liraglutide is relatively short-acting, it must be injected once every day, unlike newer once-weekly GLP-1 drugs.

Across the SUSTAIN clinical trial program, Ozempic lowered A1C by roughly 1.0 to 1.8 percentage points depending on dose and starting level, with average weight reductions of about 6 to 14 lb (roughly 2.5 to 6.5 kg) at the 0.5 mg and 1 mg doses, and more at 2 mg. In the SUSTAIN-6 cardiovascular outcomes trial (3,297 patients with type 2 diabetes at high cardiovascular risk, published in NEJM in 2016), semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% versus placebo (6.6% vs 8.9%; hazard ratio 0.74, 95% CI 0.58 to 0.95). That composite benefit was driven mainly by a significant drop in nonfatal stroke; reductions in nonfatal heart attack and cardiovascular death individually were not statistically significant, and the trial notably found a higher rate of diabetic retinopathy complications in the semaglutide group. SUSTAIN-6 was designed as a safety (non-inferiority) trial that went on to show superiority on the composite. The separate 2024 FLOW trial showed a 24% reduction in a combined kidney-and-cardiovascular outcome, supporting the 2025 chronic kidney disease indication.

In the pivotal SCALE Obesity and Prediabetes trial (NEJM, 2015), adults without diabetes lost a mean of 8.0% of body weight on liraglutide 3.0 mg versus 2.6% on placebo at 56 weeks. About 63% of liraglutide patients lost at least 5% of body weight (vs. 27% on placebo) and roughly 33% lost at least 10% (vs. 11% on placebo). However, in the head-to-head STEP 8 trial (JAMA, 2022), once-weekly semaglutide 2.4 mg produced 15.8% mean weight loss versus 6.4% for daily liraglutide 3.0 mg over 68 weeks, more than double the effect. Individual results vary and depend heavily on combining the drug with diet and activity.

The most common side effects (reported in at least 5% of patients) are gastrointestinal: nausea (about 16-20%), vomiting, diarrhea, abdominal pain, and constipation. These are usually worst early on or after a dose increase and often ease over time; eating smaller, lower-fat meals can help. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), worsening diabetic retinopathy, and allergic reactions. Ozempic carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any persistent abdominal pain, vision changes, or signs of an allergic reaction.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, typically mild-to-moderate and worst during the first weeks as the dose is increased. Headache, low blood sugar (especially in people with type 2 diabetes), increased heart rate, and injection-site reactions also occur. Serious but uncommon risks include acute pancreatitis, gallbladder disease (gallstones), and kidney problems from dehydration. Saxenda carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek urgent medical care for severe, persistent abdominal pain, signs of an allergic reaction, or a lump or swelling in the neck.

As of September 2026, NovoCare Pharmacy sells Ozempic to self-pay patients for $349/month (0.25, 0.5 or 1 mg pens) and $499/month (2 mg), and new patients pay $199/month for their first two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Ozempic pill costs $149–$299/month depending on dose. The list price is roughly $1,000 per pen package — close to what an uninsured patient pays at a regular pharmacy counter without these programs. Commercially insured patients may pay less with the manufacturer savings card (caps apply; not available with government insurance). Medicare and Medicaid typically cover Ozempic for type 2 diabetes but not for weight loss. Confirm pricing and coverage before starting.

As of 2026, Saxenda's cash price without insurance runs roughly $1,300 to $1,650 per month for a 30-day supply (five prefilled pens), varying by pharmacy. Pharmacy discount coupons (e.g., GoodRx) can cut this to around $370-$500. Insurance coverage is inconsistent, often requires prior authorization, and many commercial plans, plus Medicare, exclude weight-loss drugs entirely. Note that Novo Nordisk's $25 Saxenda Savings Card was discontinued for new enrollees in mid-2023, so it is no longer a reliable way to lower cost; uninsured patients with limited income may instead qualify for free medication through the Novo Nordisk Patient Assistance Program. A lower-cost generic liraglutide (from Teva) launched in the US in 2025 at roughly $1,165 per month, which may reduce out-of-pocket costs over time as availability expands.

Ozempic is FDA-approved for adults with type 2 diabetes to improve blood sugar control, to reduce major adverse cardiovascular events in those who also have established cardiovascular disease, and (since January 2025, based on the FLOW trial) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in those with type 2 diabetes and chronic kidney disease. It is not approved for type 1 diabetes or for weight loss on its own. Do NOT use it if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide. Use caution with a history of pancreatitis, diabetic retinopathy, or gallbladder disease, and discuss pregnancy plans with your doctor. Your prescriber makes the final eligibility call.

Saxenda is FDA-approved for adults with obesity (BMI 30 or higher) or with a BMI of 27 or higher plus at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, and for adolescents aged 12-17 who weigh more than 132 lbs (60 kg) and have obesity. It is meant to be used alongside a reduced-calorie diet and increased physical activity. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), in pregnancy, and in people with a prior serious allergic reaction to liraglutide. It should not be combined with other GLP-1 medicines and is used cautiously in those with a history of pancreatitis or gallbladder disease. Your prescriber makes the final eligibility decision.